Table 2. Baseline demographic characteristics, stratified by β2-AR genotype(homozygous variant versus wild type carriers).
| Variable | Glu27Glu (N=9) | Gln27 carriers (N=21) | Gly16Gly (N=17) | Arg16 carriers (N=13) |
|---|---|---|---|---|
| Age (yrs) | 57.3 ± 12.7 | 58.0 ± 16.1 | 55.7 ± 15.4 | 60.6 ± 14.5 |
| Men | 7 (78%) | 14 (67%) | 15 (88%)† | 6 (46%) |
| White/black/Hispanic | 8 / 1 / 0 | 19 / 0 / 2 | 16 / 1 / 0 | 11 / 0 / 2 |
| NYHA FC II/III | 9 / 0 | 18 / 3 | 15 / 2 | 12 / 1 |
| Ischemic heart disease | 4 (44%) | 7 (33%) | 8 (47%) | 3 (23%) |
| Body mass index | 32.2 ± 4.2 | 29.1 ± 5.3 | 29.6 ± 5.3 | 30.7 ± 4.9 |
| LVEF (%) | 40.0% ± 10.0% | 32.3% ± 9.5% | 34.1% ± 11.6% | 35.3% ± 8.2% |
| Background therapy | ||||
| Beta blocker (C or M#) | 4 / 5 | 11 / 10 | 7 / 10 | 8 / 5 |
| ACE inhibitor / ARB | 8 / 1 | 19 / 2 | 16 / 1 | 11 / 2 |
| Furosemide | 5 (56%) | 16 (76%) | 10 (59%) | 11 (85%) |
| Digoxin | 2 (22%) | 13 (62%) | 7 (41%) | 8 (62%) |
| Spironolactone | 4 (44%) | 8 (38%) | 6 (35%) | 6 (46%) |
| Statin | 5 (56%) | 17 (81%) | 12 (71%) | 10 (77%) |
*
Data are mean ± SD
#
C = carvedilol; M = metoprolol succinate
†
P=0.018 for sex comparing Gly16Gly and Arg16 carriers